# Safety and Efficacy Of Amber Peripheral Liquid Embolic System

> **NCT06456125** · NA · ACTIVE_NOT_RECRUITING · sponsor: **LVD Biotech S.L** · enrollment: 70 (estimated)

## Conditions studied

- Vascular Anomalies
- Hemorrhage
- Aneurysm
- Pseudoaneurysm
- Varicose Veins
- Portal Vein Embolization
- Hypervascular Tumor
- Type II Endoleak
- Pathological Organ

## Interventions

- **DEVICE:** amber SEL-P Peripheral Liquid Embolic System

## Key facts

- **NCT ID:** NCT06456125
- **Lead sponsor:** LVD Biotech S.L
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06456125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06456125, "Safety and Efficacy Of Amber Peripheral Liquid Embolic System". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06456125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*